Dr Sergey A Dzugan MD PhD
Co-founder and Chief Scientific Officer of the Dzugan Institute of Restorative Medicine, Deerfield Beach, FL. Dr. Dzugan is a former heart surgeon. International Academy of Creative Endeavors (Russia) awarded Dr. Dzugan with the honorary title of Academician for outstanding contribution to the development of new methods of hypercholesterolemia and migraine treatment. He performed presentations multiple times at the prestigious International Congress on Anti-Aging Medicine and other Medical Conferences. He is the author of 156 publications in medical journals, author of 6 books, holder of 3 patents, and author of numerous articles in health related magazines. Dr. Dzugan is a Member of the Editorial Board of the Neuroendocrinilogy Letters and a member of the Medical Advisory Board at Life Extension Magazine. He is co-founder and President of iPOMS (International Physiology Optimization Medical Society).
He was formerly a senior heart surgeon and Chief of Cardiovascular Surgery at the Donetsk Regional Medical Center in Donetsk, Ukraine. A total of 15 physicians and 25 non-physician employees required his management efforts in 25 beds department. The service area for the hospital was 5.5 million. His PhD in cardiovascular surgery was received in 1990 and pertained to heart rhythm disorders. He was Associate Professor of Medical University in Donetsk, Ukraine.
Dr. Dzugan has worked with the Cancer Center in Greenwood, MS for more than 7 years and was a principle consultant of Anti-Aging strategy and biological therapy of cancer. The Cancer Center was active in clinical research and Dr. Dzugan’s scholarly background as a clinical researcher helped proceed in a more organized and scientific fashion. The American Academy of Anti-Aging Medicine certified Dr. Dzugan in 1998.
In October 2003 he moved to Ft. Lauderdale, Florida, and became the Manager of the Advisory Department at the Life Extension Foundation. Later, he became President of Life Extension Scientific Information Inc. In August 2006, Dr. Dzugan left the Life Extensions Foundation to create the Migraine Program, a scientific organization that consults with physicians to develop the optimal plans for their patients to prevent migraine.
Dr. Dzugan has had a special training in vascular surgery, combustiology, microsurgery, arrythmology, heart surgery, genetic testing, pedagogics and psychology. Also he has since 1996 twice a year annual continuing medical education activity for credit hours in Category 1 of the Physicians’ Recognition Award of the American Medical Association.
Dr. Dzugan’s current primary interests are physiologic therapy for elevated cholesterol, migraine, fatigue, fibromyalgia, behavioral and hormonal disorders.
Dr. Dzugan has suggested a new hypothesis on hypercholesterolemia and has worked out an original statin free method regarding hypercholesterolemia treatment. He has also introduced a new approach to the treatment of migraine. Dr. Dzugan was accepted (June, 30 2006) to the International Academy of Creative Endeavors (Moscow, Russia) as a Corresponding Member of the Academy for the outstanding contribution to the development of new methods of hypercholesterolemia and migraine treatment. In December 2007, Dr. Dzugan was awarded with Honoree Medal by this Academy for the personal input into the acquisition of science, culture, physical betterment of nation and strengthening of friendship between nations. The International Academy of Creative Endeavors, an academy of world renowned thought leaders in the sciences and various other fields, awarded Dr. Dzugan with the prestigious, high honorary title of “Academician” for outstanding achievement in the field of science on January 8, 2010.
He performed presentations multiple times at the prestigious International Congress on Anti-Aging Medicine and Annual Clinical Applications for Age Management Medicine Conference. The topics of his presentations were “Hypercholesterolemia Treatment: a New Hypothesis or Just an Accident?”, “Role of Immunorestorative Therapy in Non Small-Cell Lung Cancer”, “A New Method of Migraine Treatment: The Simultaneous Restoration of Neurohormonal and Metabolic Integrity”, “Hypercholesterolemia Treatment: a New Statin Free Method”, “The Effect of Multimodal Treatment Program in Migraine Management”, “The Role of Hormonorestorative Therapy in Hypercholesterolemia Treatment”, “The Role of Hormonorestorative Therapy in the Treatment of Major Illnesses”, etc.
He also was a speaker at the Third Annual Mississippi Partnership for Cancer Control in Underserved Populations Conference. The workshop was titled “Ask the Expert: Questions on Lung Cancer”.
Dr. Dzugan is the author of 143 publications in medical journals and these publications include surgical, oncological, academic and anti-aging topics. Also, several articles were published in Life Extension Magazine and The South African Journal of Natural Medicine. He is the author of 3 books and holder of 3 patents (all related to heart surgery). Dr. Dzugan is a Member of the Editorial Board of the Neuroendocrinilogy Letters and a member of the Medical Advisory Board at Life Extension Magazine.
2016 - Age-Related Macular Degeneration. A New hypothesis.
Sergey A. Dzugan, MD, PhD
Dzugan Institute of Restorative Medicine, Deerfield Beach, FL, USA
A new hypothesis has been proposed that acquired errors of physiology, including steroidopenia,
are the root cause of age-related macular degeneration (AMD). We hypothesized that the macula
tries to increase the production of steroid hormones by increasing absorption of cholesterol, but it
cannot, due to aging enzymatic failure. This leads to drusen formation and macular degeneration.
Low hormones down regulate stem cell function, leading to an inability of stem cells to maintain
optimal macular function and structure. Also, drusen development is possibly the body's attempt
to repair micro-breaks in retinal pigment epithelium (RPE) or Bruch's membrane.
It is known that the retina is part of the central nervous system (CNS), and the retina is an
authentic steroidogenic structure of the CNS. Most cholesterol is synthesized in the neural retina
and used for retinal steroidogenesis. Steroids such as pregnenolone, DHEA, progesterone,
testosterone and estrogens are neurosteroids. It has been shown in different studies that steroids
may prevent neuronal cell death. Decreased levels of most steroids during aging make neurons
more vulnerable to damage.
We analyzed 53 patients with the dry form of macular degeneration (26 male and 27
female). Our study showed that profound deficiencies existed in DHEA and pregnenolone in
males and females, total estrogen and progesterone in females, and a moderate deficiency of
testosterone in men and women and progesterone in men. All patients were treated by a
multimodal program which included: hormonorestorative therapy with bio-identical hormones,
vitamins, minerals and different supplements. Our preliminary results showed an improvement in
dark adaptation and stability of the macula, which we suspect is a direct stimulatory effect on the
retinal pigment epithelium.
We believe that physiology optimization with the correction of steroidopenia may help to
stop the progression of age-related macular degeneration through direct effect on retina and
through potentiation of stem cells function.
2016 - Physiologic Approach to Cholesterol Regulation vs drugs.
We analyzed a difference between a physiologic approach to cholesterol regulation versus drugs’ use. Several years ago we suggested a new hypothesis of hypercholesterolemia. It implies that hypercholesterolemia is the reactive consequence of enzyme-dependent down regulation of steroid hormones biosynthesis and their interconversion. There are very few publications regarding the association of steroidopenia and hypercholesterolemia. The goal of our presentation is to determine the role of a physiologic approach to regulation of cholesterol metabolism in comparison with drugs treatment.
We analyzed the results of our two retrospective studies that included 155 patients with high cholesterol, where we used hormonorestorative therapy as a basic element of treatment. Laboratory tests included lipid profile, serum pregnenolone, dehydroepiandrosterone sulfate, total estrogen, progesterone, cortisol, total testosterone, and vitamin D-3. In all patients a deficiency or imbalance of steroid hormones were found. HT therapy included a combination of several agents such as pregnenolone, dehydroepiandrosterone (DHEA), triestrogen, progesterone, testosterone, hydrocortisone, and vitamin D-3. The follow up period ranged from 3 to 9 months.
Cholesterol levels decreased in all 155 patients treated with HT. Mean serum TC dropped by 24.6% (from 252.9 mg/dL before to 190.7 mg/dL after treatment) in the first study group (112 patients). Mean age 54.2. Serum TC completely normalized in 63.4%. 36.6% of patients still have a minimal elevation of serum TC due to non-complete optimization of steroid hormone levels.
In the second study (43 patients), HT lowered mean TC from 228.8 mg/dL to 183.7 mg/dL (19.7%) (p-0.05) in all patients. In men of mean age 58, HT statistically significantly lowered TC from 227.9 mg/dL to 177.1 mg/dL (22.3%) (p- 0.05). In women, mean age 57, TC declined from 229.2 mg/dL to 186.3 mg/dL (19%) (p- 0.05). These results were associated with statistically significant elevations in pregnenolone, DHEA Sulfate, testosterone, progesterone but not total estrogen, cortisol, or vitamin D-3 changes in both men and women.
No side effects or complications related to HT were noted.
Our studies reconfirmed our hypothesis that steroidopenia and hypercholesterolemia are closely interrelated strongly suggesting that one drives the other. The results showed that the correction of steroidopenia with the use of hormonorestorative therapy is an effective strategy for normalizing and maintaining cholesterol homeostasis. HT can significantly decrease the level of TC without any side effects that are very common with the use of drugs and can be recommended for clinical use.
Keywords: steroidopenia; hypercholesterolemia; hormonorestorative therapy; pregnenolone;
DHEA; progesterone; estrogen; cortisol; testosterone; vitamin D-3